A7655
Atenolol
≥98% (TLC), powder, β₁-adrenoceptor antagonist
동의어(들):
(±)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide, 4-[2′-Hydroxy-3′-(isopropylamino)propoxy]phenylacetamide
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C14H22N2O3
CAS 번호:
Molecular Weight:
266.34
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
249-451-7
MDL number:
제품 이름
Atenolol, ≥98% (TLC), powder
InChI key
METKIMKYRPQLGS-UHFFFAOYSA-N
InChI
1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
SMILES string
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1
assay
≥98% (TLC)
form
powder
color
white to off-white
solubility
H2O: 0.3 mg/mL, DMSO: 18 mg/mL, ethanol: 3.4 mg/mL
originator
AstraZeneca
Quality Level
Gene Information
human ... ADRB1(153)
rat ... Adrb1(24925)
유사한 제품을 찾으십니까? 방문 제품 비교 안내
관련 카테고리
Application
Atenolol is a β-adrenergic blocker and used in the management of hypertension. Atenolol has antianginal and antiarrhythmic properties.
Biochem/physiol Actions
Selective β1-adrenoceptor antagonist; antihypertensive; antianginal; antiarrhythmic.
Features and Benefits
This compound is featured on the β-Adrenoceptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Other Notes
Shelf-life of the solid is at least three years.
저장 등급
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Ganesha Rai et al.
Journal of medicinal chemistry, 52(20), 6474-6483 (2009-09-19)
Schistosomiasis is a chronic parasitic disease affecting hundreds of millions of individuals worldwide. Current treatment depends on a single agent, praziquantel, raising concerns of emergence of resistant parasites. Here, we continue our explorations of an oxadiazole-2-oxide class of compounds we
Hsin-Hui Chiu et al.
Mayo Clinic proceedings, 88(3), 271-276 (2013-01-17)
To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS). Between May 1, 2007, and September 31
Ronald V Lacro et al.
American heart journal, 165(5), 828-835 (2013-04-30)
The Pediatric Heart Network designed a clinical trial to compare aortic root growth and other short-term cardiovascular outcomes in children and young adults with Marfan syndrome randomized to receive atenolol or losartan. We report here the characteristics of the screened
Sripal Bangalore et al.
The American journal of medicine, 127(10), 939-953 (2014-06-15)
Debate exists about the efficacy of β-blockers in myocardial infarction and their required duration of usage in contemporary practice. We conducted a MEDLINE/EMBASE/CENTRAL search for randomized trials evaluating β-blockers in myocardial infarction enrolling at least 100 patients. The primary outcome
Ronald V Lacro et al.
The New England journal of medicine, 371(22), 2061-2071 (2014-11-19)
Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers. We conducted a randomized trial comparing
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.